YM-341619 - ≥99% , CAS No.643082-52-4

CAS: 643082-52-4 Cat. No.: Y646875 Summenformel: C₂₂H₂₁F₃N₆O₂ Molekulargewicht: 458.44

GRADE & PURITY ≥99%

Storage

Store at -20°C

Shipped In

Ice chest + Ice pads

Übersicht

YM-341619 (AS1617612) is a potent and orally active STAT6 inhibitor with an IC 50 of 0.70 nM. YM-341619 inhibits Th2 differentiation in mouse spleen T cells induced by IL-4 ( IC 50 =0.28 nM) without affecting Th1 cell differentiation YM-341619 is a promising compound for the the research of allergic diseases, such as allergic asthma .

In Vitro

YM-341619 (0.1-100 nM; pretreatment 30 min before IL-4) inhibits IL-4-increased STAT6 luciferase gene activity in a concentration dependent manner, exhibiting an IC 50 value of 1.5 nM in FW4 cells. YM-341619 (0.1-10 nM; pretreatment 30 min before IL-4) concentration-dependently decreases the production of IL-4 and the expression of GATA-3 mRNA in T cells cultured with IL-4. And it has no effects on the production of IFN-γ or the expression of T-bet (a Th1 transcription factor) mRNA in T cells cultured with IL-12. MCE has not independently confirmed the accuracy of these methods. They are for reference only. RT-PCRCell Line: T cells Concentration: 0.1 nM, 1 nM, 10 nM Incubation Time: Pretreatment 30 min before IL-4, then IL-4 treated for 16 hours Result: Decreased IL-4 and GATA-3 mRNA expression.

In Vivo

YM-341619 (intravenous injection; 1 mg/kg) exhibits CL tot , t 1/2 , V d values of 36.1 mL/min/kg, 1.0 hour, 3117 mL/kg, respectively. And it exhibits C max , T max , AUC, and F% values of 80 ng/mL, 0.5h, 114 ng h/mL and 25%, respectively in 8-week-old female balb/c mice . YM-341619 (oral administration; 0.003-0.03 mg/kg) suppresses the IgE level in a dose-dependent manner, but not the IgG2a level, and the ED 50 value of YM-341619 for the suppression of IgE production is 0.026 mg/kg. YM-341619 tends to decrease IL-4 production and decrease IL-13 production in a dose-dependent manner (both 57%), but does not affect IFN-γ production in DNP-Ascaris-sensitized rats. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: DNP-Ascaris-sensitized rats Dosage: 0.003-0.03 mg/kg Administration: Oral administration; 0.003-0.03 mg/kg Result: Suppressed IL-4 and IL-13 production in splenocytes derived from DNP-ascaris-sensitized rats without reducing IFN-γ production.

Form:Solid

IC50& Target:STAT6 0.70 nM (IC 50 )

Specifications

Spezifikationen & Reinheit

≥99%

Biochemische und physiologische Mechanismen

YM-341619 (AS1617612) is a potent and orally active STAT6 inhibitor with an IC 50 of 0.70 nM. YM-341619 inhibits Th2 differentiation in mouse spleen T cells induced by IL-4 ( IC 50 =0.28 nM) without affecting Th1 cell differentiation. YM-341619 is a

Storage

Store at -20°C

Verschickt in

Ice chest + Ice pads

Dieses Produkt erfordert Kühlkettenversand. Grundversand und andere Economy-Optionen sind nicht verfügbar.

Reinheit

≥99%

Namen und Kennungen

• Kanonisches Lächeln: O=C(C1=CN=C(NC2=CC=C(N3CCOCC3)C=C2)N=C1NCC4=C(F)C=CC(F)=C4F)N
• Molekulargewicht: 458.44

Chemische und physikalische Eigenschaften

• Löslichkeit: DMSO : 50 mg/mL (109.07 mM; ultrasonic and warming and heat to 60°C)

Häufig gestellte Fragen

What is the purity of this product?

This product is supplied at ≥99% purity (chemical assay). Lot-specific values are stated on the Certificate of Analysis.

How should this product be stored?

Store at ?20 °C. Freezer storage is required to maintain the specified shelf life.

How is this product shipped?

This product ships in an insulated container with ice pads. Unpack on arrival and transfer it to the storage condition stated above.

What are the CAS number, molecular formula and molecular weight?

The CAS Number is 643082-52-4, the molecular formula is C22H21F3N6O2, and the molecular weight is 458.44 g/mol.

What documentation is provided?

Available product documentation, including Certificates of Analysis (COA), Safety Data Sheets (SDS), and specification sheets, is shown in the product document area. Document availability and access follow the current site policy.